Abstract VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, caused by somatic mutations in UBA1, is an autoinflammatory disorder with diverse systemic …
I Kötter, M Krusche - Current Opinion in Rheumatology, 2025 - journals.lww.com
In the current review, we discuss the novelties for VEXAS, including pathogenic pathways, epidemiological data, diagnostic criteria and algorithms, treatment options and …
L Phan, D Hammond, NR Wilson… - Leukemia & …, 2024 - Taylor & Francis
VEXAS syndrome is a recently described entity characterized by systemic inflammatory and hematologic manifestations. The disease was first characterized by Beck et al. in 2020 in a …
T Rácz, S Burciu, T Torok, L Damian… - Medical …, 2024 - medultrason.ro
VEXAS syndrome is a recently described condition characterized by systemic inflammation, predisposition to hematologic malignancy and a high rate of venous thrombosis. Here we …
BE Fan, CLL Sum, BPL Leung, MK Ang… - … in Thrombosis and …, 2024 - thieme-connect.com
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a novel autoinflammatory syndrome due to a ubiquitin like modifier activating enzyme 1 (UBA1) …
P Breillat, B Terrier - Bulletin de l'Académie Nationale de Médecine, 2025 - Elsevier
Résumé VEXAS est un acronyme (vacuoles, enzyme E1, lié à l'X, auto-inflammatoire, somatique) qui désigne un syndrome auto-inflammatoire décrit pour la première fois en …
J Hadjadj, Y Nguyen, D Mouloudj, R Bourguiba… - 2024 - ard.bmj.com
Background: VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory disease of adults associated with somatic mutations in the UBA1 …
The use of TKIs (first imatinib, followed by second-and third-generation TKIs) in combination with conventional chemotherapy in children and young adults, or with reduced intensity in …
Als Autoinflammation bezeichnet man unphysiologische entzünd liche Prozesse im Körper, die nicht auf einer Immunantwort des adap tiven Immunsystems basieren, sondern …